<div id="readability-page-1"><p>Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Medina Manuel Hidalgo sold 1,250 shares of the business's stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $105.00, for a total value of $131,250.00. Following the transaction, the director directly owned 797 shares in the company, valued at $83,685. The trade was a 61.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.</p><ul><li>4 Healthcare Stocks With Massive Gains—and More to Come</li></ul><p>Medina Manuel Hidalgo also recently made the following trade(s): </p><ul><li>On Friday, November 7th, Medina Manuel Hidalgo sold 1,500 shares of Guardant Health stock. The shares were sold at an average price of $95.19, for a total value of $142,785.00. </li><li>On Friday, September 12th, Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. </li></ul><div><p><span></span><span>Get <strong>Guardant Health</strong> alerts:</span></p></div><h2>Guardant Health Trading Down 0.6%</h2><p>Shares of NASDAQ:GH traded down $0.59 on Wednesday, hitting $102.62. The company had a trading volume of 1,913,708 shares, compared to its average volume of 2,231,505. The stock has a market cap of $12.93 billion, a price-to-earnings ratio of -31.97 and a beta of 1.58. The stock has a 50 day moving average price of $87.13 and a 200 day moving average price of $64.63. Guardant Health, Inc. has a 1-year low of $29.91 and a 1-year high of $112.43. </p><ul><li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li></ul><p>Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same quarter in the prior year, the company posted ($0.88) EPS. The business's revenue was up 38.5% on a year-over-year basis.  Sell-side analysts anticipate that  Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities research analysts have recently issued reports on GH shares. TD Cowen boosted their price objective on Guardant Health from $63.00 to $72.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, September 25th. Piper Sandler lifted their price target on Guardant Health from $60.00 to $90.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, October 22nd. Morgan Stanley boosted their price target on Guardant Health from $105.00 to $130.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, December 1st. Canaccord Genuity Group  set a $100.00 price objective on Guardant Health in a report on Thursday, October 30th. Finally, Cowen  reiterated a &#34;buy&#34; rating on shares of Guardant Health in a research report on Thursday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $80.86.</p><ul><li>3 Fast-Growing Stocks Analysts See Doubling in Price</li></ul><p><b>Get Our Latest Research Report on Guardant Health</b></p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Allworth Financial LP lifted its position in  Guardant Health by 19.5% during the third quarter. Allworth Financial LP now owns 844 shares of the company's stock worth $53,000 after purchasing an additional 138 shares during the period.  TD Waterhouse Canada Inc. raised its position in shares of  Guardant Health by 3.2% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company's stock valued at $306,000 after buying an additional 151 shares in the last quarter.  Signaturefd LLC lifted its holdings in shares of  Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company's stock worth $33,000 after acquiring an additional 213 shares during the period.  American Century Companies Inc. lifted its holdings in shares of  Guardant Health by 0.3% during the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company's stock worth $4,439,000 after acquiring an additional 282 shares during the period.  Finally, PNC Financial Services Group Inc. boosted its position in shares of  Guardant Health by 8.3% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,016 shares of the company's stock worth $251,000 after acquiring an additional 307 shares in the last quarter. Institutional investors and hedge funds own  92.60% of the company's stock. </p><h2>Guardant Health Company Profile</h2> (Get Free Report)<p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Guardant Health</li><li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li><li>Market Momentum: 3 Stocks Poised for Major Breakouts</li><li>Value Investing: Is it a Good Strategy in 2022? <span>Hint: Always<span></span></span></li><li>3 Reasons Casey’s General Stores Will Continue Trending Higher</li><li>P/E Ratio Calculation: How to Assess Stocks</li><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2><p>Before you consider Guardant Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p><p>While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Guardant Health Director Medina Manuel Hidalgo sold 1,250 shares at $105 each, totaling $131,250. This sale reduced his position by 61.06%. The stock traded down 0.6% to $102.62. Analysts have given the stock a "Moderate Buy" rating with a target price of $80.86. Institutional investors have adjusted their positions in the company.</p>

Guardant Health (NASDAQ:GH) Director Sells $131,250.00 in Stock